BioVites announced that it has signed a strategic business agreement (MOU) and a non-disclosure agreement (NDA) with Myomar Molecular Inc. (hereinafter referred to as Myomar), a Canadian company specializing in molecular diagnostics for sarcopenia, and is launching its plans to enter the global market in earnest.
Biobits has accumulated experience in technology validation and commercialization with large corporations through collaboration with Hyundai Engineering & Construction through the Seoul Startup Hub Gongdeok Open Innovation Support Project. Building on this experience, the company has strengthened its partnership foundation for global market expansion.
Through this agreement, BioBites will utilize "Sarco-Finding," an AI-based blood and tissue data analysis technology for sarcopenia patients, to analyze Myomar's sarcopenia patient biospecimens and develop next-generation diagnostic and treatment solutions. This process is expected to expand BioBites' multi-center sarcopenia biobank, "Muscle Bank (M-Bank)," to a global level, securing clinical evidence.
BioVites CEO Lee Jeong-woo said, “This collaboration goes beyond simple technology sharing and is an opportunity to establish a global standard for the sarcopenia business,” adding, “We will continue to develop new sarcopenia drugs by utilizing the data and analysis technologies of both companies.”
Meanwhile, the global sarcopenia diagnosis and treatment market is strengthening the development of related AI and molecular diagnostic technologies.
You must be logged in to post a comment.